DE60214849D1 - Chromium/biotin behandlung von dyslipidemia - Google Patents

Chromium/biotin behandlung von dyslipidemia

Info

Publication number
DE60214849D1
DE60214849D1 DE60214849T DE60214849T DE60214849D1 DE 60214849 D1 DE60214849 D1 DE 60214849D1 DE 60214849 T DE60214849 T DE 60214849T DE 60214849 T DE60214849 T DE 60214849T DE 60214849 D1 DE60214849 D1 DE 60214849D1
Authority
DE
Germany
Prior art keywords
chromium
biotin
dyslipidemia
mug
biotin treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60214849T
Other languages
English (en)
Other versions
DE60214849T2 (de
Inventor
James R Komorowski
La Harpe Jon De
Danielle Greenberg
Vijaya Juturu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutrition 21 LLC
Original Assignee
Nutrition 21 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrition 21 LLC filed Critical Nutrition 21 LLC
Publication of DE60214849D1 publication Critical patent/DE60214849D1/de
Application granted granted Critical
Publication of DE60214849T2 publication Critical patent/DE60214849T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
DE60214849T 2001-02-27 2002-02-27 Chromium/biotin behandlung von dyslipidämie Expired - Fee Related DE60214849T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27188101P 2001-02-27 2001-02-27
US271881P 2001-02-27
PCT/US2002/006877 WO2002067953A2 (en) 2001-02-27 2002-02-27 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia

Publications (2)

Publication Number Publication Date
DE60214849D1 true DE60214849D1 (de) 2006-11-02
DE60214849T2 DE60214849T2 (de) 2007-04-26

Family

ID=23037476

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60214849T Expired - Fee Related DE60214849T2 (de) 2001-02-27 2002-02-27 Chromium/biotin behandlung von dyslipidämie

Country Status (10)

Country Link
US (2) US20020197331A1 (de)
EP (1) EP1397148B1 (de)
JP (1) JP2004521127A (de)
CN (1) CN1512887A (de)
AT (1) ATE339961T1 (de)
CA (1) CA2438063A1 (de)
DE (1) DE60214849T2 (de)
ES (1) ES2271242T3 (de)
PT (1) PT1397148E (de)
WO (1) WO2002067953A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043106A1 (en) * 2002-08-28 2004-03-04 Anfinsen Jon R. Methods and systems for determining and controlling glycemic responses
WO2004047765A2 (en) * 2002-11-22 2004-06-10 Shaklee Corporation Compositions, methods, and kits for weight loss and inhibiting the loss of lean body mass
US7744930B2 (en) * 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
WO2007065444A1 (en) * 2005-12-09 2007-06-14 Saibot Aps A method for evaluating the potential of a compound for use in therapy
EP1978984B1 (de) * 2006-02-01 2015-06-10 Nestec S.A. Ernährungssystem und verfahren für ein längeres leben
CA2649103C (en) 2006-04-12 2018-09-04 Interhealth Nutraceuticals, Inc. Tri-valent chromium compounds, compositions and methods of use
TW200829178A (en) * 2006-09-07 2008-07-16 Abbott Lab Controlled glycemic response sweetened cereal product
US20130071491A1 (en) * 2006-12-18 2013-03-21 Jose De J. Berrios Extruded Legume Food Products Containing Yeast Autolysate
CA2931881C (en) * 2007-01-31 2018-12-11 Nutrition 21, Inc. Use of chromium histidinate for treatment of cardiometabolic disorders
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
CA2828572C (en) 2011-03-01 2021-02-23 Jds Therapeutics, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
ES2395529B1 (es) * 2011-06-08 2014-04-11 Pri, S.A. Combinación sinérgica para el tratamiento de la diabetes mellitus tipo 2.
US20150258078A1 (en) * 2014-03-12 2015-09-17 Alexander R. Shikhman Compositions containing berberine and pantethine and methods for treatment of lipid metabolism disorders
WO2017139337A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
EP3443849A4 (de) * 2016-04-14 2020-01-15 TableMark Co., Ltd. Nahrungsmittelzusammensetzung oder kombination zur senkung des blutzuckerspiegels oder verringerung des gi-wertes

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1234567A (en) * 1915-09-14 1917-07-24 Edward J Quigley Soft collar.
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
USRE33988E (en) * 1980-08-08 1992-07-07 The United States of America as repesented by the Secretary of Agriculture Dietary supplementation with essential metal picolinates
JPS5927833A (ja) * 1982-08-06 1984-02-14 Advance Res & Dev Co Ltd コレステロール乃至トリグリセリド低下剤
US5194615A (en) * 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
US4954492A (en) * 1983-07-08 1990-09-04 The William Seroy Group Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
US5028599A (en) * 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5032608A (en) * 1986-09-10 1991-07-16 Dudrick Stanley J Method and substrate composition for treating atherosclerosis
US4921877A (en) * 1986-10-27 1990-05-01 Abbott Laboratories Liquid nutritional formula for glucose intolerance
US5087623A (en) * 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5175156A (en) * 1987-11-30 1992-12-29 Nutrition 21 Chromic picolinate treatment
US6140304A (en) * 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
US5087624A (en) * 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5106836A (en) * 1991-02-22 1992-04-21 Clintec Nutrition Co. Enteral diet
US5114963A (en) * 1991-03-13 1992-05-19 Medicis Corporation Method of reducing serum levels of lipoprotein(A)
US5597585A (en) * 1995-12-26 1997-01-28 Williams; Andrew H. Vitamin/mineral composition
US5937597A (en) * 1996-07-18 1999-08-17 Ykk Architectural Products Inc. Multi-window sash and batten attachment structure
HUP0003713A2 (hu) * 1997-08-08 2001-04-28 Nutrition 21 Króm és biotin tartalmú gyógyászati készítmény II típusú diabétesz kezelésére
US5914326A (en) * 1997-08-08 1999-06-22 Ambi Inc. Method for promoting weight and fat loss
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
UA77660C2 (en) * 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
US6579866B2 (en) * 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning

Also Published As

Publication number Publication date
CN1512887A (zh) 2004-07-14
WO2002067953A2 (en) 2002-09-06
WO2002067953A3 (en) 2002-11-21
ES2271242T3 (es) 2007-04-16
ATE339961T1 (de) 2006-10-15
EP1397148A2 (de) 2004-03-17
CA2438063A1 (en) 2002-09-06
EP1397148B1 (de) 2006-09-20
US20050214385A1 (en) 2005-09-29
JP2004521127A (ja) 2004-07-15
DE60214849T2 (de) 2007-04-26
US20020197331A1 (en) 2002-12-26
PT1397148E (pt) 2006-11-30

Similar Documents

Publication Publication Date Title
ATE339961T1 (de) Chromium/biotin behandlung von dyslipidemia
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
PT1056856E (pt) Factor neurotrofico cliliar modificado processo de preparacao e sua utilizacao
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
EP1576956A3 (de) Chromium/Biotin Behandlung von Typ-II Diabetes
ES2184808T3 (es) Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12.
BR0009718A (pt) Processo de tratamento
DE69831576T2 (de) Chromium/biotin behandlung von typ-ii diabetes
BRPI0409716A (pt) derivados de 2-acilamino-4-feniltiazol, seu preparo e sua aplicação em terapêutica
BRPI0009719B8 (pt) processo de tratamento
WO2000059487A3 (en) Flupirtine in the treatment of fibromyalgia and related conditions
SE9101815D0 (sv) Behandling av sjukdom foerbunden med hiv-infektioner
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
RS8504A (en) Novel cyclohexil sulphones
WO2001072322A3 (en) High dosage parenteral administration of lactoferrin
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
EP1447090B8 (de) Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen
ATE305796T1 (de) Präparationen von vitamin e in kombination mit afamin
DE60216292D1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
Roberts A New Root for an Old Crux, Ps. XXII 17c
RU2004102562A (ru) Способ лечения ограниченной склеродермии
RU2002109392A (ru) Способ лечения больных псориазом
TH23084A (th) วิธีของการรักษา
UA32580C2 (uk) Засіб для лікування паралітичної непрохідності кишечнику
RU98113874A (ru) Способ лечения угревой болезни у женщин

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee